amycretin - Search News

Novo Nordisk, amycretin

Hosted on MSN · 1h

Novo Nordisk shares surge on results of new obesity drug trial

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share price on Friday. View on euronews

Novo Nordisk next-gen shot shows 22% weight loss in early results

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.

Pharmabiz · 2h

Novo Nordisk announces positive results from phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

Novo Nordisk announces positive results from phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity: Bagsværd, Denmark Monday, January 27, 2025, 13:00

BioPharma Dive2d

Novo shares climb on early data for dual-acting obesity drug

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

2don MSN

Why Novo Nordisk Stock Jumped a Lucky 7.7% Today

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results